Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Asks ODAC To Ponder Shift Away From Single-Arm Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

At its Feb. 8 meeting on issues surrounding confirmatory post-marketing studies, the Oncologic Drugs Advisory Committee will discuss whether and when randomized studies should be required to secure accelerated approval.

You may also be interested in...



Farydak Confirmatory Trial To Come Years After Accelerated Approval

Despite the agency’s preference that confirmatory trials generally be under way at the time of accelerated approval, Novartis’ panobinostat Phase III trial isn’t expected to begin for approximately three years.

Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval

Data from the pivotal Phase I trial studying crizotinib in NSCLC patients demonstrates significant increase in one- and two-year survival against historical controls.

Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval

Data from the pivotal Phase I trial studying crizotinib in NSCLC patients demonstrates significant increase in one- and two-year survival against historical controls.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel